Metabolic Imaging Using Hyperpolarized Pyruvate-Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts.
Lionel MignionStefania AcciardoFlorian GourgueNicolas JoudiouXavier CaignetRose-Marie GoebbelsCyril CorbetOlivier FeronCaroline BouzinPatrice D CaniJean-Pascal MachielsSandra SchmitzBénédicte F JordanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This study constitutes the first in vivo demonstration of cetuximab-induced metabolic changes in cetuximab-sensitive HNSCC PDTXs that were not present in resistant tumors. Using metabolic imaging, we were able to identify hyperpolarized 13C-pyruvate as a potential marker for response and resistance to the EGFR inhibitor in HNSCC.